Cannabidiol for early treatment of Sturge-Weber syndrome
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether giving a medicine called Epidiolex (a purified form of CBD) to babies with Sturge-Weber syndrome before they have seizures can prevent or delay the start of seizures and improve their development.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Sturge-Weber syndrome
- Your baby is between 1 and 18 months old
- Brain scan shows the condition affects at least three brain areas or both sides of the brain
- Your baby has never had a seizure
- Your baby has not taken any seizure medicine or cannabis products recently
- Your baby has no serious liver, diabetes, or bleeding problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at switching children with Dravet or Lennox Gastaut syndrome from artisanal CBD products to a standardized FDA-approved CBD medication called Epidiolex, to see if it works as well or better for seizure control.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
This study tests whether a cannabis-derived medicine called cannabidiol (CBD) can help children with Sanfilippo syndrome, a rare genetic disorder. It may be a good fit for children who have already tried other treatments or whose disease is more advanced.
This study tests a gradual dose increase of CBD oil (Epidiolex) to see if it helps reduce seizures in adults with Lennox-Gastaut syndrome. It's for people who haven't tried CBD before or haven't used it in at least 3 months.
This trial tests a full-spectrum cannabis extract to see if it reduces seizures in people with tuberous sclerosis complex (TSC) whose seizures have not been controlled by other treatments. If it works, it could offer a new option for managing hard-to-treat epilepsy.
This study tests a new CBD patch placed on the skin to see if it can reduce seizures in people with Dravet syndrome or Lennox-Gastaut syndrome. The patch delivers CBD slowly over time, and the goal is to help control seizures that are not well managed by current medications.
Hear when a new Sturge - Weber Syndrome (SWS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.